Biodexa announces recruitment of first patient in Phase 2 tolimidone study

Biodexa Pharmaceuticals (BDRX) announced the recruitment of the first patient in a Phase 2 study of tolimidone in Type 1 Diabetes. The study is an Investigator Initiated Trial conducted by the University of Alberta Diabetes Institute. The study will measure C-peptide levels and HbA1c after three months compared with baseline and the number of hyperglycemic events initially in 12 patients across three dose groups. The study may be expanded in due course.